{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-100115","form_type":"8-K","ticker":"QNRX","cik":"0001671502","company_name":"Quoin Pharmaceuticals, Ltd.","filed_at":"2023-09-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.797476+00:00","generated_at":"2026-06-10T19:09:33.520155+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Quoin grants exclusive license for QRX003 in Singapore to Farma Mondo","bullets":["Exclusive license to Farma Mondo SA to commercialize QRX003 in Singapore.","Licensee must file for regulatory approvals within 6 months of Quoin's FDA/EMA approval.","Financial terms not disclosed; royalties payable to Quoin.","Parties to negotiate supply agreement for product manufacture and supply."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-100115","json":"https://secwatch.observer/filing/0001104659-23-100115.json","markdown":"https://secwatch.observer/filing/0001104659-23-100115.md","text":"https://secwatch.observer/filing/0001104659-23-100115.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671502/000110465923100115/0001104659-23-100115-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671502/000110465923100115/tm2325985d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T19:09:33.520155+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6cbc89b95905dfb44333e5f03f68aea5d7fe3f82","claim":"Quoin Pharmaceuticals, Ltd. entered into Exclusive License and Distribution Agreement with Farma Mondo SA valued at Exclusive license to commercialize QRX003 in Singapore, royalty-bearing (effective 2023-09-01).","evidence_excerpt":"On September 6, 2023, Quoin Pharmaceuticals Ltd. (the “Company”) entered into an Exclusive License and Distribution Agreement, effective as of September 1, 2023 (the “License Agreement”), with Farma Mondo SA, a company incorporated under the laws of Switzerland (“Farma Mondo”). Pursuant to the License Agreement, the Company granted to Farma Mondo an exclusive license under its Product Technology (as defined in the License Agreement) to commercialize, upon receipt of applicable regulatory approvals, pharmaceutical product QRX003 (in finished dosage form for human use) in Singapore.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1671502/000110465923100115/0001104659-23-100115-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Farma Mondo SA"},{"label":"Value","value":"Exclusive license to commercialize QRX003 in Singapore, royalty-bearing"},{"label":"Effective","value":"2023-09-01"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}